Identifying New Memory and Brain Markers for Early Alzheimer's Disease
Principal Investigator
Helena Gellersen, PhD
German Center for Neurodegenerative Diseases
Magdeburg, Germany
About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$199,967
Active Dates
July 01, 2024 - June 30, 2026
Grant ID
A2024013F
Mentor(s)
Goals
This project aims to identify new cognitive and neuroimaging markers associated with early stages of Alzheimer’s disease, which can identify different disease stages and subtypes.
Summary
Despite newly available treatments for Alzheimer’s disease, dementia subtype specificity is important to determine prior to treatment to ensure safe and efficacious outcomes. Optimized cognitive assessments and imaging biomarkers are also essential for early detection and to monitor disease progression.
This project will address these challenges by developing new cognitive and neural markers sensitive to the early effects of Alzheimer’s. These markers can be used to screen for subtle memory changes, classify by subtype, and identify signatures of healthy brain function that can clarify mechanisms of disease-modifying effects on memory in early-phase clinical trials.
Unique and Innovative
The DELCODE study of the German Center for Neurodegenerative Diseases is the only one worldwide that can disentangle longitudinal effects of Alzheimer’s disease on two memory networks which are differentially affected by early tau and amyloid. It uses memory tasks that were optimised to tap into these networks and which are superior to standard clinical tests as specific markers. The novel modelling procedures I will use can identify disease subtypes and estimate the time between subsequent abnormal biomarker changes to determine the utility of the new markers to index intervention windows.
Foreseeable Benefits
Insights gained from this project will provide stage- and subtype-specific cognitive and neural markers which can help researchers and clinicians to screen for individuals at an early disease stage, stratify them into subgroups, provide a time estimate for a window of opportunity for intervention prior to irreversible atrophy, identify functional brain markers to index disease-modifying effects to be used for proof-of-concept in early phase drug trials, and monitor progression and treatment response with precise cognitive markers which could in the future be used for digital remote assessment.
Grants
Related Grants
Alzheimer's Disease Research
Staging Alzheimer's Disease Using Blood Samples
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Gemma Salvadó, PhD
Staging Alzheimer's Disease Using Blood Samples
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Gemma Salvadó, PhD
Alzheimer's Disease Research
Shining a Light on How Early Tau-Related Brain Changes Affect Memory Loss
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Martin Dahl, PhD
Shining a Light on How Early Tau-Related Brain Changes Affect Memory Loss
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Martin Dahl, PhD
Alzheimer's Disease Research
Iron Spreading Patterns in Alzheimer's Disease
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Louise Van Der Weerd, PhD
Iron Spreading Patterns in Alzheimer's Disease
Active Dates
July 01, 2023 - June 30, 2026
Principal Investigator
Louise Van Der Weerd, PhD